Literature DB >> 32304075

Animal Model Contributions to Congenital Metabolic Disease.

Corinna A Moro1, Wendy Hanna-Rose2.   

Abstract

Genetic model systems allow researchers to probe and decipher aspects of human disease, and animal models of disease are frequently specifically engineered and have been identified serendipitously as well. Animal models are useful for probing the etiology and pathophysiology of disease and are critical for effective discovery and development of novel therapeutics for rare diseases. Here we review the impact of animal model organism research in three examples of congenital metabolic disorders to highlight distinct advantages of model system research. First, we discuss phenylketonuria research where a wide variety of research fields and models came together to make impressive progress and where a nearly ideal mouse model has been central to therapeutic advancements. Second, we review advancements in Lesch-Nyhan syndrome research to illustrate the role of models that do not perfectly recapitulate human disease as well as the need for multiple models of the same disease to fully investigate human disease aspects. Finally, we highlight research on the GM2 gangliosidoses Tay-Sachs and Sandhoff disease to illustrate the important role of both engineered traditional laboratory animal models and serendipitously identified atypical models in congenital metabolic disorder research. We close with perspectives for the future for animal model research in congenital metabolic disorders.

Entities:  

Year:  2020        PMID: 32304075     DOI: 10.1007/978-981-15-2389-2_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

1.  High Dose Versus Low Dose Syngeneic Hepatocyte Transplantation in Pex1-G844D NMRI Mouse Model is Safe but Does Not Achieve Long Term Engraftment.

Authors:  Tanguy Demaret; Jonathan Evraerts; Joachim Ravau; Martin Roumain; Giulio G Muccioli; Mustapha Najimi; Etienne M Sokal
Journal:  Cells       Date:  2020-12-30       Impact factor: 6.600

Review 2.  The rapidly evolving view of lysosomal storage diseases.

Authors:  Giancarlo Parenti; Diego L Medina; Andrea Ballabio
Journal:  EMBO Mol Med       Date:  2021-01-18       Impact factor: 12.137

3.  Suppression of exaggerated NMDAR activity by memantine treatment ameliorates neurological and behavioral deficits in aminopeptidase P1-deficient mice.

Authors:  Young-Soo Bae; Sang Ho Yoon; Young Sook Kim; Sung Pyo Oh; Woo Seok Song; Jin Hee Cha; Myoung-Hwan Kim
Journal:  Exp Mol Med       Date:  2022-08-03       Impact factor: 12.153

Review 4.  Inborn errors of metabolism: Lessons from iPSC models.

Authors:  Rubén Escribá; Raquel Ferrer-Lorente; Ángel Raya
Journal:  Rev Endocr Metab Disord       Date:  2021-07-09       Impact factor: 6.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.